EUVIMEDEUVIMED entdecken
Leitlinie

Significant haemoglobinopathies: A guideline for screening and diagnosis

Barbara J Bain iD, Yvonne Daniel, Joan Henthorn, Barbara de la Salle, Amanda Hogan, Noémi B A Roy iD, Ciaran Mooney, Lisa Langabeer, David C Rees iD, BSH Committee

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18794 ↗

Kurz gefasst

Leitlinie in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Barbara J Bain und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haematology, St Mary's Hospital Campus of Imperial College, St Mary's Hospital, London, UK. Hauptthemen laut MEDLINE: Hemoglobinopathies, Anemia, Sickle Cell, Thalassemia, Hematology. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antenatal screening/testing of pregnant women should be carried out according to the guidelines of the National Health Service (NHS) Sickle Cell and Thalassaemia Screening Programme. Newborn screening and, when necessary, follow‐up testing and referral, should be carried out according to the guidelines of the NHS Sickle Cell and Thalassaemia Screening Programme. All babies under 1 year of age arriving in the United Kingdom should be offered screening for sickle cell disease (SCD). Preoperative screening for SCD should be carried out in patients from ethnic groups in which there is a significant prevalence of the condition. Emergency screening with a sickle solubility test must always be followed by definitive analysis. Laboratories performing antenatal screening should utilise methods that are capable of detecting significant variants and are capable of quantitating haemoglobins A 2 and F at the cut‐off points required by the national antenatal screening programme. The laboratory must ensure a provisional report is available for antenatal patients within three working days from sample receipt.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemoglobinopathiesAnemia, Sickle CellThalassemiaHematologyInfant, NewbornFemaleHumansPregnancyState MedicineNeonatal Screening

Stichwörter der Autor:innen

genetic disordershaemoglobinopathieslaboratory haematologysickle cell anaemiasickle cell diseasethalassaemia

Autor:innen und Institutionen

  • Centre for Haematology, St Mary's Hospital Campus of Imperial College, St Mary's Hospital, London, UK.
  • Synnovis, Guy's and St Thomas Hospital, London, UK.
  • The NHS Sickle Cell and Thalassaemia (SCT) Screening Programme, London, UK.
  • UK NEQAS Haematology, West Hertfordshire Hospitals NHS Trust, Watford, UK.
  • Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Department of Haematology, St Vincent's Hospital, Dublin, Ireland.

ORCID-Profile: Barbara J Bain, Noémi B A Roy, David C Rees

Zitieren

APA

Bain, B. J., Daniel, Y., Henthorn, J., de la Salle, B., Hogan, A., Roy, N. B. A., Mooney, C., Langabeer, L., Rees, D. C., & BSH Committee (2023). Significant haemoglobinopathies: A guideline for screening and diagnosis. British Journal of Haematology. https://doi.org/10.1111/bjh.18794

Vancouver

Bain BJ, Daniel Y, Henthorn J, de la Salle B, Hogan A, Roy NBA, et al. Significant haemoglobinopathies: A guideline for screening and diagnosis. British Journal of Haematology. 2023. doi:10.1111/bjh.18794

BibTeX
@article{Bain2023,
  author = {Bain, Barbara J and Daniel, Yvonne and Henthorn, Joan and de la Salle, Barbara and Hogan, Amanda and Roy, Noémi B A and Mooney, Ciaran and Langabeer, Lisa and Rees, David C and BSH Committee, BSH Committee},
  title = {Significant haemoglobinopathies: A guideline for screening and diagnosis},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18794}
}
Kostenlos starten →